WCB Alberta Psychedelic Therapy: Coverage, Evidence, and the Prior-Auth Process (2026)

If you are an injured worker or first responder in Alberta with an accepted PTSD or chronic pain claim, WCB Alberta may review ketamine treatment as part of your care. Coverage is decided case-by-case, not automatically. This guide explains what to ask the board, who qualifies, and what the evidence shows.

Medically reviewed by Jacque Lovely, RN, MN, MBA, PMP, Reg #74334 on 2026-05-28.

Key takeaways

• WCB Alberta reviews ketamine and esketamine treatment requests for compensable psychiatric and chronic pain conditions through its own procedure. Coverage is never automatic, and the specifics change over time, so confirm the current procedure and requirements directly with WCB Alberta.
• Only a treating specialist (a neurologist, psychiatrist, physiatrist, or chronic pain specialist) can submit the prior-authorization request. Confirm the board's current request form and documentation requirements with WCB Alberta.
• Alberta's Bill 30 (the Workers' Compensation Amendment Act, 2018) created a presumption that PTSD diagnosed in designated first responders is work-related. This can speed up claim acceptance, but it does not automatically approve any specific treatment.
• In a randomized controlled trial, 67% of participants with chronic PTSD who received repeated intravenous ketamine met the treatment-responder threshold, compared with 20% who received an active placebo [Feder 2021]. The trial was small (30 people), so the result needs confirmation in larger studies.
• Psilocybin and MDMA are not covered by WCB Alberta. Legal access to these substances requires Health Canada authorization on a case-by-case basis, initiated by a physician, with no guarantee of approval.
• ATMA CENA supports a worker's application; WCB decides coverage. ATMA CENA does not submit the request and does not decide whether you are covered.

If you have a WCB Alberta claim and want to understand your options, you can book a free 15-minute information call to discuss your compensable diagnosis and treatment pathway with ATMA CENA's clinical team.

---

Does WCB Alberta cover psychedelic-assisted therapy?

WCB Alberta does not pay for psychedelic-assisted therapy as a standard benefit. Instead, it reviews ketamine and esketamine treatment requests on a case-by-case basis under its own treatment-decision procedure [WCB Alberta]. That procedure applies to psychiatric and chronic pain conditions that result from a compensable workplace injury, including treatment-resistant depression and other DSM-5 diagnoses. Because the exact procedure, forms, and criteria are updated periodically, confirm the current details directly with WCB Alberta. Approval is not automatic and depends on clinical justification from a treating specialist. In short: the right question is not "does WCB pay for this?" but "how do I ask the board, and what does my specialist need to submit?"

The process is started by the treating specialist, not by the worker or the clinic. The specialist submits a written prior-authorization request and documents that standard treatments have been tried without enough benefit. WCB then refers the request to an internal Medical Consultant and may recommend a specialist psychiatric consultation before making a decision.

Psilocybin and MDMA are not covered by WCB Alberta. For compensable PTSD, legal access to these substances requires Health Canada authorization on a case-by-case basis, initiated by a physician, and these authorizations declined sharply in 2025 [PsyCan 2025]. The realistic WCB-reviewed pathway in Alberta in 2026 involves ketamine and esketamine specifically.

For a cross-provincial comparison of how workers' compensation boards approach this treatment, see the sibling provincial guides for WSIB in Ontario and WorkSafeBC in British Columbia below.

---

Who qualifies: first responders, injured workers, and compensable conditions

Workers who may be eligible for a WCB Alberta ketamine prior-authorization request include those with a compensable diagnosis of treatment-resistant depression, PTSD, or a chronic pain condition resulting from a workplace injury. The board's procedure also sets out additional eligibility criteria, which typically include the following. Confirm the current criteria with WCB Alberta [WCB Alberta]:

• Age 18 or older
• No history of a primary psychotic disorder
• Able to provide informed consent
• Not pregnant or breastfeeding
• No known allergy to ketamine

Meeting these criteria does not guarantee approval. It means the treating specialist can make the case to the board.

First responders and Alberta's Bill 30

Alberta's Workers' Compensation Amendment Act, 2018 (Bill 30) created a legal presumption that PTSD diagnosed in a designated first responder arose out of and in the course of employment, unless the contrary is proven [Bill 30 AB 2018]. This shifted the burden of proof off the worker and can speed up access to WCB benefits. Designated occupations covered by Alberta's presumptive PTSD provision generally include:

• Police officers
• Firefighters (full-time and part-time)
• Paramedics
• Peace officers who hold the title of Sheriff
• Correctional officers
• Emergency dispatchers (911 operators)

Note that RCMP members are federally employed and are not covered under this provincial presumption, and that community peace officers and bylaw officers are not automatically included. If you are unsure whether your role qualifies, the board or a workers' advocate can confirm.

Why this matters, and what it does not do: Bill 30 applies to the underlying PTSD diagnosis and claim acceptance. It does not automatically approve a specific treatment such as ketamine. A separate prior-authorization request is still required after the claim is accepted. The presumption removes the burden of proving your PTSD is work-related, which can meaningfully shorten the road to claim acceptance and to the treatment pathway. For the full cross-provincial picture, see first responder PTSD and presumptive legislation in Canada.

Workers outside the designated first-responder list who have a compensable PTSD or chronic pain diagnosis can also pursue a ketamine prior-authorization request. Their claims usually require more documentation of work-relatedness, but they are reviewed under the same procedure.

---

The evidence base: ketamine for PTSD and chronic pain

The honest summary: the evidence for ketamine in PTSD and chronic pain is real but still emerging. The most rigorous trials are small, and the science is stronger for some uses than others. Below are the strongest peer-reviewed findings, with their limits stated plainly.

Ketamine for PTSD

The most rigorous published trial of ketamine for PTSD comes from Feder and colleagues, published in the American Journal of Psychiatry in 2021 [Feder 2021]. In this trial, 30 adults with chronic PTSD were randomly assigned to six infusions of intravenous ketamine or midazolam (an active placebo) over two weeks. At week 2, PTSD symptom severity on the CAPS-5 scale was 11.88 points lower in the ketamine group than in the midazolam group. Among the ketamine group, 67% met the treatment-responder threshold compared with 20% in the midazolam group [Feder 2021]. The result is encouraging, but with only 30 participants and follow-up of two weeks, it needs confirmation in larger, longer studies.

Ketamine for veterans and first responders

A meta-analysis and systematic review of 11 studies (384 military members) evaluated ketamine for depression, PTSD, and chronic pain in veteran and active-duty populations [Liu 2024]. The pooled effect was large, but the authors note significant publication bias and recommend cautious interpretation [Liu 2024]. This population maps closely to the Alberta WCB audience of first responders and uniformed workers, which is why the caution matters: the findings are promising, not settled.

Ketamine for chronic pain

For compensable chronic pain, a 2023 systematic review and meta-analysis of intravenous ketamine for chronic pain found a statistically significant reduction in pain scores (a mean difference of about 1 point on a standard pain scale) [Odutola 2023]. Ketamine has been studied most in complex regional pain syndrome (CRPS) and neuropathic pain. As with the PTSD data, the trials are variable in size and quality.

The Alberta context

A community ketamine program in Edmonton (Misericordia and Grey Nuns hospitals) treats highly treatment-resistant depression through the public system. Among the first 50 patients, 44% responded within their initial intravenous course [Chrenek 2023]. This program is a Canadian reference point for delivering ketamine in Alberta's healthcare setting, and it shows the treatment is established here, not experimental in the loose sense.

Key stat: In the Feder 2021 PTSD trial, 67% of the ketamine group met the treatment-responder threshold, versus 20% of the active-placebo group [Feder 2021]. Limits to keep in mind: small sample (30 people), single site, and follow-up of only two weeks. This is a reason for cautious optimism, not a promise of a particular result.

---

Psilocybin and MDMA: the case-by-case Health Canada pathway for compensable PTSD

Psilocybin and MDMA have the strongest Phase 3 trial evidence for PTSD. In the MAPP1 trial of MDMA-assisted therapy, 67% of participants in the MDMA group no longer met the diagnostic criteria for PTSD, versus 32% in the placebo group [Mitchell 2021]. The MAPP2 confirmatory trial replicated these results in a more diverse population [Mitchell 2023].

Despite this evidence, neither psilocybin nor MDMA is covered by WCB Alberta. Legal access to these substances for therapeutic use requires Health Canada authorization, granted on a case-by-case basis and initiated by a physician [Health Canada 2022]. That authorization is not guaranteed, and approval rates declined significantly in 2025 [PsyCan 2025]. The realistic WCB-reviewed pathway for compensable PTSD in Alberta in 2026 remains ketamine and esketamine.

If you are interested in psilocybin- or MDMA-assisted therapy and also have a WCB claim, discuss both pathways with your treating physician. ATMA CENA can support the preparation of a physician-initiated Health Canada authorization request for eligible patients who wish to pursue this route, alongside or separately from a WCB claim.

---

The WCB Alberta prior-authorization process: step by step

The path from first call to treatment usually follows these stages. Confirm the current forms and requirements with WCB Alberta [WCB Alberta]:

1. Establish a compensable diagnosis. The worker files a WCB claim and the treating physician documents the diagnosis using DSM-5 criteria. For designated first responders, Bill 30's presumption can speed up this step.

2. Document that conventional treatments have not worked well enough. The treating specialist records trials of standard care (medication, evidence-based psychotherapy such as CBT or EMDR, or other indicated treatments) that did not produce enough improvement.

3. Identify a treating specialist willing to prescribe ketamine. The prescriber must be a neurologist, psychiatrist, physiatrist, or chronic pain specialist. Under current CPSA guidance, a family physician may prescribe non-intravenous ketamine in consultation with a psychiatrist.

4. Submit the prior-authorization request. The treating specialist sends the board's written request to WCB Alberta, documenting the compensable diagnosis, prior treatment failures, the proposed treatment, and the clinical rationale. Confirm the current request form with WCB Alberta.

5. WCB medical review. An internal WCB Medical Consultant reviews every request. WCB may recommend a specialist psychiatric consultation before deciding.

6. Decision. WCB sends a written decision to both the worker and the treating specialist.

7. Treatment begins, if approved. Treatment is delivered in a qualifying clinical setting under physician oversight, in line with CPSA accreditation requirements.

ATMA CENA's clinical team can book a free information call to walk workers and case managers through this process, explain how documentation is typically assembled, and show how ATMA CENA's intake fits within the prior-authorization timeline.

---

Alberta's regulatory framework: CPSA standards and clinic accreditation

Alberta has established formal regulatory infrastructure for psychedelic-assisted psychotherapy. The College of Physicians and Surgeons of Alberta (CPSA) sets the prescribing, administration, and oversight expectations for ketamine in the province [CPSA 2026]. Key points from current CPSA guidance:

• Intravenous (IV) ketamine must be administered in a CPSA-accredited Non-Surgical Health Facility (NSHF) with an appropriately qualified clinical team.
• Non-IV routes (oral, intranasal, intramuscular) may be provided in qualifying community clinical settings, within the prescriber's scope, in consultation with a psychiatrist.
• The guidance does not create new prescribing authority or approve new indications.
• Ketamine is approved by Health Canada as an anaesthetic. Use for PTSD, depression, anxiety, and chronic pain is off-label.

ATMA CENA's clinics are licensed by Alberta Health and accredited through the College of Physicians and Surgeons of Alberta. They deliver non-intravenous ketamine (intranasal, including Spravato and compounded formulations, intramuscular, and oral) under physician oversight, in line with current CPSA standards. ATMA CENA does not offer intravenous ketamine.

Watch out: Not every clinic that advertises "ketamine therapy" in Alberta holds full accreditation for psychedelic-assisted psychotherapy. If you are pursuing WCB-reviewed treatment, confirm a clinic's accreditation as part of your due diligence. You can review ATMA CENA's member clinics and current accreditation documentation.

---

How ATMA CENA works with WCB Alberta case managers and treating physicians

ATMA CENA's role in a WCB Alberta pathway is to support the application and deliver the therapy, not to decide coverage. WCB decides coverage. The treating specialist submits the request. ATMA CENA delivers the therapy if it is approved.

In practice, ATMA CENA's clinical process for WCB-referred workers includes:

• A free 15-minute information call. Workers or case managers can discuss whether ketamine-assisted therapy is appropriate, whether the compensable diagnosis fits the WCB procedure, and what documentation the treating specialist will need.
• Intake and screening. An ATMA CENA practitioner reviews the clinical history, treatment records, and compensable diagnosis to confirm appropriateness and to support the specialist's prior-authorization documentation.
• In-person medical assessment. An ATMA CENA-affiliated physician reviews the worker's history and, where appropriate, contributes to coordinated documentation for the WCB submission.
• Coordination with existing treaters. ATMA CENA works alongside, not instead of, a worker's current psychiatrist, psychologist, or counsellor. Through ATMA CENA's CoCare program, ATMA CENA can partner with a worker's existing therapist where that therapist has the appropriate training and a service agreement is in place. This matters for first responders who may already have mental-health relationships through occupational health or employee assistance programs.
• Documentation support. ATMA CENA can prepare clinical documentation of treatment history and rationale to support the specialist's prior-authorization submission. ATMA CENA does not submit on the worker's behalf; only the treating specialist can.
• Treatment delivery. If WCB approves, ATMA CENA delivers the approved program (preparation, medicine, and integration sessions) at an Alberta clinic.

If a WCB claim is under appeal or a prior-authorization is denied, ATMA CENA can help with documentation that may support an appeal, in coordination with the treating specialist and, where applicable, legal counsel.

Workers and first responders ready to discuss next steps can book a free information call with ATMA CENA's clinical team to map the pathway specific to their WCB Alberta claim.

This article is general information about coverage and process, not financial, tax, or legal advice. Confirm coverage details, forms, and eligibility with WCB Alberta and your treating specialist.

---

Frequently asked questions

Will WCB Alberta pay for ketamine therapy?

WCB Alberta does not pay for ketamine therapy automatically. It reviews ketamine and esketamine requests case-by-case for compensable psychiatric and chronic pain conditions. A treating specialist must submit a prior-authorization request, and the board makes the final decision. Confirm the current forms and requirements with WCB Alberta [WCB Alberta].

How do I get a psychological injury claim accepted in Alberta?

File a WCB claim and have your physician document the diagnosis using DSM-5 criteria and link it to your work. For designated first responders, Bill 30 presumes PTSD is work-related, which removes the burden of proving the connection. Other workers usually need more documentation of work-relatedness. Once the claim is accepted, any specific treatment such as ketamine still requires a separate prior-authorization request [WCB Alberta; Bill 30 AB 2018].

Which WCB conditions qualify for a ketamine prior-authorization request?

The procedure covers psychiatric and chronic pain conditions resulting from a compensable injury, including treatment-resistant depression and DSM-5 psychiatric diagnoses. Eligibility criteria typically include being 18 or older, no history of a primary psychotic disorder, ability to consent, not being pregnant or breastfeeding, and no ketamine allergy. Confirm the current criteria with WCB Alberta [WCB Alberta].

Who are the designated first responders under Alberta's Bill 30?

Designated occupations for presumptive PTSD coverage generally include police officers, firefighters (full-time and part-time), paramedics, peace officers who hold the title of Sheriff, correctional officers, and emergency dispatchers. RCMP members are federally employed and are not covered under the provincial presumption [Bill 30 AB 2018].

Does presumptive PTSD automatically cover ketamine therapy?

No. Bill 30 helps your underlying PTSD claim get accepted by removing the burden to prove it is work-related. It does not approve any specific treatment. A separate ketamine prior-authorization request is still required after the claim is accepted [WCB Alberta].

Can ATMA CENA submit the WCB prior-authorization request for me?

No. WCB Alberta requires the prior-authorization request to be submitted by the treating specialist, specifically a neurologist, psychiatrist, physiatrist, or chronic pain specialist. ATMA CENA can help with the clinical documentation that supports the submission, but ATMA CENA cannot be the submitting party [WCB Alberta].

What if WCB denies the request?

You can appeal a WCB decision through WCB Alberta's dispute resolution process. Additional clinical justification, documentation of further treatment failures, or specialist consultation reports may support an appeal. Workers' compensation lawyers and Alberta's Office of the Worker Adviser can provide guidance.

Does WCB cover psilocybin or MDMA therapy in Alberta?

No. Psilocybin and MDMA are not covered by WCB Alberta. Legal access is only through Health Canada authorization, on a case-by-case basis and initiated by a physician. That authorization is not guaranteed and declined significantly in 2025 [PsyCan 2025; Health Canada 2022].

Is an ATMA CENA Alberta clinic an approved WCB provider?

ATMA CENA's Alberta clinics are licensed by Alberta Health and accredited through the College of Physicians and Surgeons of Alberta. Because these credentials are reviewed periodically, confirm current accreditation status at the time of your inquiry, and confirm approved-provider status with WCB Alberta.

What does ketamine-assisted therapy actually involve?

Ketamine-assisted therapy at ATMA CENA has three phases: preparation sessions (typically two to four appointments to establish context and a safety plan), medicine sessions (ketamine administered in a supervised clinical setting, typically 40 to 90 minutes depending on the route), and integration sessions (processing the experience and applying it in ongoing therapy). The total program length depends on the WCB-approved protocol.

How do I reach ATMA CENA about a WCB Alberta enquiry?

ATMA CENA operates clinics in Edmonton and Calgary. Workers and case managers can begin with a free information call at atmacena.com/information-call, or email info@atmacena.com.

---

Compliance notes

Ketamine off-label framing

Ketamine is approved by Health Canada as an anaesthetic. Use for PTSD, depression, anxiety, and chronic pain is off-label and regulated by provincial medical regulators, including the College of Physicians and Surgeons of Alberta (CPSA). Under current CPSA guidance, intravenous (IV) ketamine must be administered in a CPSA-accredited Non-Surgical Health Facility (NSHF). Non-IV routes (oral, intranasal, intramuscular) may be provided in qualifying community clinical settings by a qualified prescriber in consultation with a psychiatrist. All ketamine-assisted therapy at ATMA CENA is delivered under physician oversight, in line with current CPSA standards [CPSA 2026].

Psilocybin and MDMA framing

Psilocybin and MDMA are restricted drugs under Canada's Controlled Drugs and Substances Act. Patient access to psilocybin- or MDMA-assisted therapy is available only through Health Canada authorization on a case-by-case basis, initiated by a physician. That authorization is not guaranteed. It is primarily considered for adults with treatment-resistant major depressive disorder or distress associated with a life-threatening illness (psilocybin) and for adults with PTSD (MDMA). Approval rates declined significantly in 2025 [PsyCan 2025; Health Canada 2022].

---

About the author

Reverdi Darda, RN, BScN, Reg #61707 | CEO & Founder, ATMA CENA

Reverdi Darda, RN is CEO & Founder of ATMA CENA and a Registered Nurse with over three decades of experience in healthcare operations, community engagement, policy development, and strategic planning. A recognized leader in mental health access, Reverdi has dedicated her career to advancing evidence-based treatment models and advocating for policy change that prioritizes effective care. She founded ATMA CENA to expand practitioner and public access to psychedelic-assisted therapy across Canada.

View Reverdi Darda's profile and other articles

---

Sources

1. WCB Alberta. Ketamine or Esketamine Treatment Decision Procedure. Workers' Compensation Board of Alberta. https://www.wcb.ab.ca/about-wcb/procedures-manual/pharmaceutical-ketamine-and-esketamine.html
2. Government of Alberta (2018). Workers' Compensation Amendment Act, 2018 (Bill 30): presumptive PTSD for first responders. https://www.rankandfile.ca/albertas-bill-30-psychological-injuries-deeming-and-rt/
3. CPSA (College of Physicians and Surgeons of Alberta) (2026). Ketamine prescribing, administration and oversight expectations. https://cpsa.ca/physicians/standards-of-practice/
4. Health Canada (2022). Notice to stakeholders: requests involving psychedelic-assisted psychotherapy. https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/requests-special-access-program-psychedelic-assisted-psychotherapy.html
5. PsyCan (2025). PsyCan Discovers Sharp Decline in Health Canada Approvals for Doctors Seeking Legal Psychedelic Therapy for Patients. https://psychedelicscanada.org/media/2025/09/psycan-discovers-sharp-decline-in-health-canada-approvals-for-doctors-seeking-legal-psychedelic-therapy-for-patients
6. Feder, A., Costi, S., Rutter, S.B., et al. (2021). A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder. American Journal of Psychiatry, 178(2), 193-202. PMID: 33397139. https://pubmed.ncbi.nlm.nih.gov/33397139/
7. Mitchell, J.M. et al. (2021). MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine, 27(6), 1025-1033. PMID: 33972795. https://pubmed.ncbi.nlm.nih.gov/33972795/
8. Mitchell, J.M. et al. (2023). MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nature Medicine, 29(10), 2473-2480. PMID: 37709999. https://pubmed.ncbi.nlm.nih.gov/37709999/
9. Chrenek, C., Duong, T., Khullar, A., McRee, C., Thomas, R., Swainson, J. (2023). Use of ketamine for treatment resistant depression: updated review of literature and practical applications to a community ketamine program in Edmonton, Alberta, Canada. Frontiers in Psychiatry, 14:1283733. PMID: 38260793. https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2023.1283733/full
10. Odutola, O. et al. (2023). IV ketamine infusion therapy for chronic pain: A systematic review and meta-analysis. Medicine Advances. https://onlinelibrary.wiley.com/doi/full/10.1002/med4.45
11. Liu, J.J.W., Ein, N., Gervasio, J. et al. (2024). Ketamine in the effective management of chronic pain, depression, and posttraumatic stress disorder for Veterans: A meta-analysis and systematic review. Frontiers in Psychiatry. https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2024.1338581/full

---

Related articles in this cluster

• First Responder PTSD and Presumptive Legislation in Canada
• WSIB Ontario Psychedelic Therapy
• WorkSafeBC Psychedelic Therapy

---

Last updated: 2026-05-28. This article is reviewed every 3 months given time-sensitive regulatory and coverage information.